Government-Owned Inventions; Availability for Licensing, 48439 [2016-17419]

Download as PDF Federal Register / Vol. 81, No. 142 / Monday, July 25, 2016 / Notices Child Health and Human Development, NIH, 6710B Rockledge Drive, Room 2314, Bethesda, MD 20892, (301) 496–8535, dhann@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: July 19, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–17423 Filed 7–22–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development. ADDRESSES: Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD, 20850–9702. FOR FURTHER INFORMATION CONTACT: Information on licensing and codevelopment research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850–9702, Tel. 240–276–5515 or email ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Title of invention: Novel metastatic serous epithelial ovarian cancer (SEOC) genetically engineered mouse models, mstockstill on DSK3G9T082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:27 Jul 22, 2016 Jkt 238001 cell lines, and orthotopic models based on Rb, p53 and/or Brca 1/2 inactivation useful for biomarker discovery and preclinical testing. Description of Technology: The high mortality rate from ovarian cancers can be attributed to late-stage diagnosis and lack of effective treatment. Despite enormous effort to develop better targeted therapies, platinum-based chemotherapy still remains the standard of care for ovarian cancer patients, and resistance occurs at a high rate. One of the rate limiting factors for translation of new drug discoveries into clinical treatments has been the lack of suitable preclinical cancer models with high predictive value. NCI CAPR has developed Tri-allelic K18–T121 tg/∂ /Brca1 fl/fl /p53 fl/fl SEOC GEM Model, GEM-derived SEOC orthotopic mouse model, and biological materials derived therefrom, with several key histopathologic, immunophenotypical, and genetic features of human SEOC. SEOC GEMs were utilized to create orthotopic immunocompetent transplant models, and to generate synchronized cohorts of mice suitable for preclinical studies. NCI CAPR conducted studies that determine these models are tractable for use in routine efficacy studies and demonstrate the utility of these models in evaluating the potential efficacy of novel therapeutics for ovarian cancer. Potential Commercial Applications: • These models serve as a foundation for preclinical research and evaluation of efficacy of novel therapeutics for ovarian cancer. • The GEM models described here can be used to develop cell lines and allograft models for evaluating drug potency relative to Brca1 mutation status. • These mouse models provide the opportunity for evaluation of effective therapeutics, including prediction of differential responses in Brca1-wild type and Brca1–deficient tumors and development of relevant biomarkers. Value Proposition: • Novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer • Similarity to human ovarian cancer based on transcriptional profiling • Suitable preclinical cancer models with high predictive value. Development Stage: Pre-clinical (in vivo validation). Inventor(s): Simone Difilippantonio, Terry Van Dyke, Zoe Weaver Ohler, Ludmila Szabova, Sujata Bupp, Yurong Song, Chaoying Yin. PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 48439 Intellectual Property: Research use— no patent protection will be sought. Publications: 1. Szabova L., Yin C., Bupp S., et al. Perturbation of Rb, p53 and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer research. 2012;72(16):4141–4153. 2. Szabova L., Bupp S., Kamal M., et al. Pathway-Specific Engineered Mouse Allograft Models Functionally Recapitulate Human Serous Epithelial Ovarian Cancer. Katoh M., ed. PLoS ONE. 2014;9(4):e95649. Collaboration Opportunity: Researchers at the NCI seek licensing and/or co-development research collaborations for the commercialization of agents for the treatment of SEOC. Contact Information: Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email: john.hewes@ nih.gov. Dated: July 11, 2016. John D. Hewes, Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute. [FR Doc. 2016–17419 Filed 7–22–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel Pediatric Heart Network Clinical Research Centers (UG1). Date: August 17–18, 2016 Time: 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\25JYN1.SGM 25JYN1

Agencies

[Federal Register Volume 81, Number 142 (Monday, July 25, 2016)]
[Notices]
[Page 48439]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-17419]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD, 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD 20850-9702, Tel. 240-276-5515 or email 
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Novel metastatic serous epithelial ovarian 
cancer (SEOC) genetically engineered mouse models, cell lines, and 
orthotopic models based on Rb, p53 and/or Brca 1/2 inactivation useful 
for biomarker discovery and preclinical testing.
    Description of Technology: The high mortality rate from ovarian 
cancers can be attributed to late-stage diagnosis and lack of effective 
treatment. Despite enormous effort to develop better targeted 
therapies, platinum-based chemotherapy still remains the standard of 
care for ovarian cancer patients, and resistance occurs at a high rate. 
One of the rate limiting factors for translation of new drug 
discoveries into clinical treatments has been the lack of suitable 
preclinical cancer models with high predictive value.
    NCI CAPR has developed Tri-allelic K18-T121 tg/+ /Brca1 
fl/fl /p53 fl/fl SEOC GEM Model, GEM-derived SEOC 
orthotopic mouse model, and biological materials derived therefrom, 
with several key histopathologic, immunophenotypical, and genetic 
features of human SEOC. SEOC GEMs were utilized to create orthotopic 
immunocompetent transplant models, and to generate synchronized cohorts 
of mice suitable for preclinical studies. NCI CAPR conducted studies 
that determine these models are tractable for use in routine efficacy 
studies and demonstrate the utility of these models in evaluating the 
potential efficacy of novel therapeutics for ovarian cancer.
    Potential Commercial Applications:
     These models serve as a foundation for preclinical 
research and evaluation of efficacy of novel therapeutics for ovarian 
cancer.
     The GEM models described here can be used to develop cell 
lines and allograft models for evaluating drug potency relative to 
Brca1 mutation status.
     These mouse models provide the opportunity for evaluation 
of effective therapeutics, including prediction of differential 
responses in Brca1-wild type and Brca1-deficient tumors and development 
of relevant biomarkers.
    Value Proposition:
     Novel resource for evaluating disease etiology and 
biomarkers, therapeutic evaluation, and improved imaging strategies in 
epithelial ovarian cancer
     Similarity to human ovarian cancer based on 
transcriptional profiling
     Suitable preclinical cancer models with high predictive 
value.
    Development Stage: Pre-clinical (in vivo validation).
    Inventor(s): Simone Difilippantonio, Terry Van Dyke, Zoe Weaver 
Ohler, Ludmila Szabova, Sujata Bupp, Yurong Song, Chaoying Yin.
    Intellectual Property: Research use--no patent protection will be 
sought.
    Publications:

1. Szabova L., Yin C., Bupp S., et al. Perturbation of Rb, p53 and 
Brca1 or Brca2 cooperate in inducing metastatic serous epithelial 
ovarian cancer. Cancer research. 2012;72(16):4141-4153.
2. Szabova L., Bupp S., Kamal M., et al. Pathway-Specific Engineered 
Mouse Allograft Models Functionally Recapitulate Human Serous 
Epithelial Ovarian Cancer. Katoh M., ed. PLoS ONE. 2014;9(4):e95649.

    Collaboration Opportunity: Researchers at the NCI seek licensing 
and/or co-development research collaborations for the commercialization 
of agents for the treatment of SEOC.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: john.hewes@nih.gov.

    Dated: July 11, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-17419 Filed 7-22-16; 8:45 am]
BILLING CODE 4140-01-P